Why Iovance Biotherapeutics, Inc.’s (IOVA) Stock Is Up 23.02%
As of Tuesday, September 29, Iovance Biotherapeutics, Inc.’s IOVA share price has surged by 23.02%, which has investors questioning if this is right time to sell.Jenna Brashear
Stock Evaluator: Iovance Biotherapeutics, Inc. (IOVA)
Iovance Biotherapeutics, Inc. IOVA
$14.22
-0.02
-0.11%
October 2, 2026 4:00:00 PM
EST
Volume: 11,913,692
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Commentary & Analysis
Why Iovance Biotherapeutics, Inc.’s (IOVA) Stock Is Up 34.24%
As of Tuesday, September 29, Iovance Biotherapeutics, Inc.’s IOVA share price has surged by 34.24%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Iovance Biotherapeutics, Inc.’s (IOVA) Stock Is Up 8.56%
As of Thursday, September 17, Iovance Biotherapeutics, Inc.’s IOVA share price has surged by 8.56%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Iovance Biotherapeutics, Inc.’s (IOVA) Stock Is Up 6.22%
As of Monday, September 14, Iovance Biotherapeutics, Inc.’s IOVA share price has surged by 6.22%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Iovance Biotherapeutics, Inc.’s (IOVA) Stock Is Down 11.12%
As of Friday, August 21, Iovance Biotherapeutics, Inc.’s IOVA share price has dipped by 11.12%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | IOVA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6,439.0 | $250.1 | 72% |
|
| Shares Out (Mil) | 450.2 | 54.0 | 87% |
|
| Institutional Ownership | 89.8% | 93.1% | 57% |
|
| Float (Mil) | 394.3 | 41.4 | 83% |
|
| Beta | 0.83 | 0.95 | 50% |
|
| Avg Daily Volume (000s) | 21,726 | 661 | 99% |
|
| Price Change (52-week) |
543.2% | 49.5% | 100% |
|
| Growth | IOVA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.5% | na |
|
| Net Income (5yr) | (8.5%) | (10.1%) | 31% |
|
| EPS (5yr) | 10.2% | 15.8% | 47 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (19.7%) | (15.7%) | 34% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 8 | |
| Current EPS | ($0.087) | ($0.457) | ($0.237) | |
| Month Ago EPS | ($0.096) | ($0.496) | ($0.287) | |
| # Rev Up | 3 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.125) | ($0.564) | ($0.319) | |
| Year/Year Chg | (17.1%) | (58.2%) | (111.3%) | |
| Financials | IOVA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $325 | $37 | 36% |
|
| Net Income (TTM) (Mil) | ($290) | ($44) | 5% |
|
| EPS (TTM) | ($0.706) | ($1.600) | 25% |
|
| Operating Cash Flow (TTM) (Mil) | ($264) | ($33) | 3% |
|
| Net Cash Flow (TTM) (Mil) | ($22) | $2 | 26% |
|
| Long-Term Debt (Q1) (Mil) | $43 | $4 | 38% |
|
| Enterprise Value (Q1) (Mil) | $4,391 | $175 | 61% |
|
| Valuation | IOVA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 8.77 | 2.36 | 89% |
|
| P/E | na | 18.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | IOVA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 48.4% | 67.3% | 60% |
|
| Net Margin | (89.1%) | (74.8%) | 8% |
|
| ROA | (31.8%) | (47.6%) | 16% |
|
| ROE | (40.4%) | (54.9%) | 17% |
|
| Liabilities to Assets | 19.6% | 29.3% | 13% |
|
| F-Score | 5 | 3 | 50% |
|
Iovance Biotherapeutics, Inc. did not pass any screens on 10/2/2026.
